# NEONAX (NCT02047513)

> Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer

No report yet. It can be ordered.

- Drugs tested: nab-paclitaxel plus gemcitabine
- Indication: resectable pancreatic ductal adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02047513
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: AIO-Studien-gGmbH
- Conditions: Resectable Pancreatic Cancer; Ductal Adenocarcinoma of the Pancreas
- Interventions: perioperative nab-paclitaxel/gemcitabine; adjuvant nab-paclitaxel/gemcitabine
- Enrollment: 127
- Primary outcome: Time to Disease free survival (DFS)

## Indexed commentary on NEONAX so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- YouTube: 1

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=neonax-nct02047513

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02047513", "email": "<work email>"}; the inbox owner confirms by the emailed link.